Last reviewed · How we verify
placebo sitagliptin
Placebo sitagliptin is an inert formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient and produces no therapeutic effect.
Placebo sitagliptin is an inert formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient and produces no therapeutic effect. Used for Clinical trial control arm (not a therapeutic indication).
At a glance
| Generic name | placebo sitagliptin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo sitagliptin is a non-active comparator used in randomized controlled trials to assess the efficacy of active sitagliptin (a DPP-4 inhibitor). It allows researchers to distinguish genuine drug effects from placebo response and natural disease progression. The formulation is identical in appearance and administration to active sitagliptin but lacks the active ingredient.
Approved indications
- Clinical trial control arm (not a therapeutic indication)
Common side effects
Key clinical trials
- The Role of Phosphodiesterase Inhibitors in Incretin Secretion (PHASE1)
- Pharmacogenetics of Response to Sitagliptin (PRS) (PHASE4)
- Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
- Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (PHASE4)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo sitagliptin CI brief — competitive landscape report
- placebo sitagliptin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI